Fingerprint
Dive into the research topics where Philip Gold is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Al Baghdadi, T., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Crysler, O. V., Mileham, K. F., Farrington, L. C., Adesunloye, B., Dublis, S. A., Astsaturov, I., Calfa, C. J., Bleeker, J., Khalil, M., Thota, R., Cannon, T. L., Alese, O. B., Gold, P. J., Hafez, N., Baron, A. D. & Meric-Bernstam, F. & 9 others, , Jun 12 2025, In: JCO Precision Oncology. 9Research output: Contribution to journal › Article › peer-review
-
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Huang, A. H., Lee, G. Y., Lu, C. A., Sahin, I. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., Coveler, A. L., Malhotra, J., Forbes, V. E., Gold, P. J., Chiorean, E. G. & Hsieh, R. W., Dec 2025, In: JCO Oncology Practice. 12Research output: Contribution to journal › Review article › peer-review
2 Scopus citations -
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial
Raghav, K. P. S., Guthrie, K. A., Tan, B., Denlinger, C. S., Fakih, M., Overman, M. J., Dasari, N. A., Corum, L. R., Hicks, L. G., Patel, M. S., Esparaz, B. T., Kazmi, S. M., Alluri, N., Colby, S., Gholami, S., Gold, P. J., Chiorean, E. G., Kopetz, S., Hochster, H. S. & Philip, P. A., Apr 10 2025, In: Journal of Clinical Oncology. 43, 11, p. 1348-1357 10 p.Research output: Contribution to journal › Article › peer-review
10 Scopus citations -
Sunitinib in Patients with Breast Cancer with FGFR1 or FGFR2 Amplifications or Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study
Calfa, C. J., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Ahn, E. R., Burness, M. L., Gogineni, K., Rohatgi, N., Al Baghdadi, T., Conlin, A., Gaba, A., Hamid, O., Krishnamurthy, J., Gavini, N. J., Gold, P. J., Rodon, J., Rueter, J., Thota, R., Grantham, G. N. & Hinshaw, D. C. & 3 others, , Feb 1 2024, In: JCO Precision Oncology. 8, e2300513.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Morris, V. K., Guthrie, K. A., Kopetz, S., Breakstone, R., Karasic, T. B., Hu, Z. I., Colby, S., Fakih, M., Gholami, S., Gold, P. J. & Philip, P. A., Jan 20 2024, In: Journal of Clinical Oncology. 42, p. TPS234-TPS234Research output: Contribution to journal › Review article › peer-review
1 Scopus citations